ArticlePulmonary circulation
Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension.
Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2016Guideline
- eNOS Uncoupling-ER Stress-Mitochondrial Dysfunction Axis in the Development of Pulmonary Hypertension.JACC. Basic to translational science · 2026Article
- Solid-State Gas Sensors with Ni-Based Sensing Materials for Highly Selective Detecting NOx.Sensors (Basel, Switzerland) · 2024Article
- Nitric Oxide Releasing Nanomaterials for Cardiovascular Applications.JACC. Basic to translational science · 2024Review
- Administering Nitric Oxide (NO) with High Flow Nasal Cannulas: A Simple Method.Advances in respiratory medicine · 2024Article
- Recent advances on endogenous gasotransmitters in inflammatory dermatological disorders.Journal of advanced research · 2022Review
- Potential Prophylactic Treatments for COVID-19.Viruses · 2021Review
- Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.Comprehensive Physiology · 2021Article
- Drug Treatment of Pulmonary Hypertension in Children.Paediatric drugs · 2020Review
- Management of Pulmonary Arterial Hypertension in the Pediatric Patient.Current cardiology reports · 2019Review
- Progress and Promise of Nitric Oxide-Releasing Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Review
- Nitric oxide and pulmonary arterial hypertension.Global cardiology science & practice · 2017Review
- Combined oral administration of L-arginine and tetrahydrobiopterin in a rat model of pulmonary arterial hypertension.Pulmonary circulation · 2017Article
- Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH.Pharmaceutical research · 2016Article
- A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension.Journal of cardiovascular translational research · 2016Article
- Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?Current hypertension reports · 2015Review
- Increasing pulmonary artery pulsatile flow improves hypoxic pulmonary hypertension in piglets.Journal of visualized experiments : JoVE · 2015Article
- Ca(2+) and ion channels in hypoxia-mediated pulmonary hypertension.International journal of clinical and experimental pathology · 2015Review
- Drug treatment of pulmonary hypertension in children.Paediatric drugs · 2014Review
- Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease of the pulmonary vasculature with a high morbidity and mortality. Its pathobiology involves at least three interacting pathways - prostacyclin (PGI(2)), endothelin, and nitric oxide (NO). Current treatments target these three pathways utilizing PGI(2) and its analogs, endothelin receptor antagonists, and phosphodiesterase type-5 (PDE-5) inhibitors. Inhaled nitric oxide (iNO) is approved for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term/near-term neonates. As a selective pulmonary vasodilator, iNO can acutely decrease pulmonary artery pressure and pulmonary vascular resistance without affecting cardiac index or systemic vascular resistance. In addition to delivery via the endotracheal tube, iNO can also be administered as continuous inhalation via a facemask or a pulsed nasal delivery. Consistent with a deficiency in endogenously produced NO, long-term pulsed iNO dosing appears to favorably affect hemodynamics in PAH patients, observations that appear to correlate with benefit in uncontrolled settings. Clinical studies and case reports involving patients receiving long-term continuous pulsed iNO have shown minimal risk in terms of adverse events, changes in methemoglobin levels, and detectable exhaled or ambient NO or NO(2). Advances in gas delivery technology and strategies to optimize iNO dosing may enable broad-scale application to long-term treatment of chronic diseases such as PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.